In re Application of Rahman et al.
Application No. 10/717,378

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method of treating a cellular proliferative disease, comprising administering to a mammalian host a pharmaceutical composition comprising:
   (a) a therapeutically effective amount of liposomal entrapped irinotecan also comprising cardiolipin, wherein the liposomal entrapped irinotecan demonstrates a irinotecan plasma concentration 200-fold higher than conventional irinotecan and
   (b) a pharmaceutically acceptable excipient.
2. (Original) The method of claim 1, wherein said mammalian host is a human.
3. (Original) The method of claim 1, wherein approximately 3-fold less irinotecan accumulates in cardiac tissue as compared to conventional irinotecan.
4. Canceled
5. (Currently Amended) The method of claim 1, wherein said pharmaceutical composition has a plasma half-life of ~~is~~ approximately 10-fold greater than ~~with~~ the conventional irinotecan formulation.
6. (Original) The method of claim 1, wherein said cardiolipin is selected from ~~the~~ a group consisting of natural cardiolipin and synthetic cardiolipin.
7. (Original) The method of claim 1, wherein said liposome bears a negative charge.
8. (Original) The method of claim 1, wherein said liposome bears a positive charge.
9. (Currently Amended) The method of claim 1, wherein at least a portion of ~~said liposome-entrapped~~ irinotecan is complexed with cardiolipin.
10. Canceled
11. (Currently Amended) A therapeutic composition comprising ~~a~~ liposome entrapped irinotecan, wherein said liposome comprises a first liposome forming material comprising cardiolipin and a second liposome forming material and wherein the liposome entrapped irinotecan demonstrates a irinotecan plasma concentration 200-fold higher than conventional irinotecan.
12. (Original) The composition of claim 11, wherein a portion of said cardiolipin is complexed with irinotecan.
13. (Currently Amended) The composition of claim ~~12~~ 11, wherein said liposome entrapped irinotecan comprises vesicles having a size of about 5 μm or less.

14. (Currently Amended)The composition of claim ~~12~~ 11, wherein said liposome entrapped irinotecan comprises vesicles having a size of about 1 μm or less.
15. (Currently Amended) The composition of claim ~~12~~ 11, wherein said liposome entrapped irinotecan comprises vesicles having a size of about 0.5 μm or less.
16. (Currently Amended) The composition of claim ~~12~~ 11, wherein said liposome entrapped irinotecan comprises vesicles having a size of about 0.1 μm or less.
17. (Currently Amended) The composition of claim 11, wherein said second liposome-forming material is a lipid selected from ~~the~~ a group consisting of phosphatidylcholine, cholesterol, α-tocopherol, dipalmitoyl phosphatidylcholine and phosphatidylserine.
18. (Currently Amended) The composition of claim 11, wherein said cardiolipin is selected from ~~the~~ a group consisting of natural cardiolipin and synthetic cardiolipin.
19. (Original) The method of claim 11, wherein said liposome bears a negative charge.
20. (Original) The method of claim 11, wherein said liposome bears a positive charge.
21. (Original) The method of claim 11, wherein said liposome is neutral.
22. Canceled
23. (Original) A method for the treatment of mammalian cancer comprising administering a therapeutically effective amount of the composition of claim 11 to a subject in need thereof.

24.-46. Canceled